570 related articles for article (PubMed ID: 19476973)
1. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
Saraf S; Wellsted D; Sharma S; Gorog DA
Thromb Res; 2009 Sep; 124(4):447-51. PubMed ID: 19476973
[TBL] [Abstract][Full Text] [Related]
2. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
Tanaka KA; Szlam F; Kelly AB; Vega JD; Levy JH
Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
[TBL] [Abstract][Full Text] [Related]
4. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
5. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
[TBL] [Abstract][Full Text] [Related]
6. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
[TBL] [Abstract][Full Text] [Related]
7. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
8. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
Yamamoto J; Inoue N; Otsui K; Ishii H; Gorog DA
Thromb Res; 2014 May; 133(5):919-26. PubMed ID: 24613697
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization.
Norgard NB; Saya S; Hann CL; Hennebry TA; Schechter E; Dale GL
J Cardiovasc Pharmacol; 2008 Dec; 52(6):536-9. PubMed ID: 19034031
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
Dyszkiewicz-Korpanty A; Olteanu H; Frenkel EP; Sarode R
Platelets; 2007 Nov; 18(7):491-6. PubMed ID: 17852774
[TBL] [Abstract][Full Text] [Related]
11. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
Sibbing D; Braun S; Jawansky S; Vogt W; Mehilli J; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2008 Jan; 99(1):121-6. PubMed ID: 18217143
[TBL] [Abstract][Full Text] [Related]
12. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
Lordkipanidzé M; Pharand C; Palisaitis DA; Schampaert E; Diodati JG
Thromb Res; 2009 Nov; 124(5):546-53. PubMed ID: 19419755
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
16. The Retention Index Test Homburg (RTH-II): Response to clopidogrel and comparison with aggregometry and CD62P-expression.
Klinkhardt U; Wenzel E; Harder S
Platelets; 2006 Feb; 17(1):42-8. PubMed ID: 16308186
[TBL] [Abstract][Full Text] [Related]
17. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
18. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
Gurbel PA; Bliden KP; Etherington A; Tantry US
Thromb Res; 2007; 121(1):107-15. PubMed ID: 17400283
[TBL] [Abstract][Full Text] [Related]
20. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
Steinhubl SR; Oh JJ; Oestreich JH; Ferraris S; Charnigo R; Akers WS
Thromb Res; 2008; 121(4):527-34. PubMed ID: 17631948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
